In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At ...

Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a open-label study ...

Follow the latest news updates on the Sean "Diddy" Combs trial. Defense hammers ex-assistant for posts supporting Combs after alleged assaults.

Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the full breadth of the immune system to protect ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

BEACON and Open-Label Extension Study Design and Data Summary: ...

Neoadjuvant and adjuvant pembrolizumab added to standard care significantly improves event-free survival in HNSCC.

Topline data expected in H2 2026 LONDON and CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited ("Beacon Therapeutics" or "the Company"), a leading clinical-stage ...

Abatacept reduces the rate of progression to RA and improves the rate of remission in patients with palindromic rheumatism ...

Conference Call Information Rhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, July 9, to discuss these clinical data. Participants may register for the ...

Luspatercept-aamt shows significant survival benefits and transfusion independence in lower-risk MDS, reshaping treatment ...